LDS/Medical Tests/EsoGuard Methylation Assay for Barrett’s Esophagus

EsoGuard Methylation Assay for Barrett’s Esophagus

Esophageal adenocarcinoma is a serious cancer with only a 20% survival rate at 5 years. The only known antecedent of esophageal adenocarcinoma is Barrett’s esophagus, a condition where the normal squamous lining of the lower esophagus is replaced by columnar gastrointestinal epithelium. Patients with Barrett’s esophagus are at high risk of developing esophageal adenocarcinoma. The exact mechanism behind the causation of Barrett’s esophagus is unknown but attributed to gastrointestinal reflux (heartburn). Most cases of Barrett’s esophagus remain undiagnosed or diagnosed late when a metaplastic transformation has occurred.

EsoGuard Methylation Assay is a molecular technique used for the screening of Barrett’s esophagus and predicts the risk of esophageal adenocarcinoma based on esophogeal cells collected by a non-endoscopic method. The assay employs aberrant DNA methylation patterns as molecular markers for Barrett’s esophagus. Vimentin and CyclinA1 methylation at 31 different sites of the DNA is screened via next-generation sequencing. Studies in patients with GERD symptoms indicate that this testing is an acceptable alternative to endoscopic examination and biopsy. If positive the patient, should undergo endoscopy with multiple biopsies to confirm the diagnosis of BE and evaluate for the presence of carcinoma.

  • Useful in screening individuals for Barrett’s esophagus
  • Helpful in monitoring patients with gastrointestinal reflux disease
A positive test result indicates the presence of Barrett’s esophagus and confirmation via esophagogastroduodenoscopy is required. A negative test result suggests the absence of Barrett’s esophagus but cannot be used to rule out BE. In patients with significant risk factors and symptoms endoscopic evaluation may be warranted despite a negative test.

Negative

Methylation-specific real-time PCR detection system, Next generation sequencing (NGS).

Specimen: Esophageal brushings obtained via EsoCheck cell collection device

EsoCheck cell collection device: Consists of a swallowable catheter with a deflated balloon that is inflated in the stomach. Balloon consists of ridges that collect cells from the gastroesophageal junction when the catheter is pulled out. Cells are then collected in a vial.

Biopsy, esophagus, Barrett's-Associated Neoplasia, Cytology, Barrett's-Associated Neoplasia, FISH, CBC, Comprehensive metabolic panel.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login